Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Individualized High Dose Methotrexate in Treating Younger Patients With Cancer and Significant Risk for Side Effects

Trial Status: administratively complete

This phase I trial studies how well individualized high dose methotrexate works in treating younger patients with cancer and significant risk for side effects. Individualized high-dose methotrexate may reduce the chances that the level of methotrexate in the blood is too high. When the levels are too high, there may be an increase in side effects. Monitoring and potentially adjusting the final amount of methotrexate given based on the levels of methotrexate in blood samples in the first 24 hours may help prevent side effects in patients with a previous history of side effects from methotrexate or who are at high risk for having side effects.